# A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome

> **NCT03054896** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Dana-Farber Cancer Institute** · enrollment: 69 (actual)

## Conditions studied

- Richter Syndrome

## Interventions

- **DRUG:** Venetoclax
- **OTHER:** DA-EPOCH-R
- **OTHER:** R-CHOP

## Key facts

- **NCT ID:** NCT03054896
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2017-03-08
- **Primary completion:** 2024-12-01
- **Final completion:** 2027-12-01
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2025-08-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03054896

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03054896, "A Phase II Study of Venetoclax in Combination With Dose-adjusted EPOCH-R or R-CHOP for Patients With Richter's Syndrome". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT03054896. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*